

Exploring new MRI techniques - a study in healthy volunteers and healthy patients

Submission date 09/11/2023	Recruitment status Recruiting	☐ Prospectively registered ☐ Protocol
Registration date 14/11/2023	Overall study status Ongoing	☐ Statistical analysis plan ☐ Results
Last Edited 13/04/2026	Condition category Other	☐ Individual participant data ☒ Record updated in last year

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-different-ways-of-doing-mri-scans-hevomri>

Background and study aims

Magnetic Resonance Imaging (or MRI) plays an important role in detecting, diagnosing, and monitoring different diseases in the body. We often use contrast-enhanced MRI, which enhances and improves the quality of the MRI images. This type of MRI involves an injection of a chemical substance often called gadolinium-based contrast agent.

In this study we aim to develop novel imaging methods for cancer diagnostics and treatment monitoring. When developing a new method, we need healthy volunteers to help define the limits of "normal." Similarly, it is useful to know what the images look like in healthy patients, i.e. patient with a known genetic predisposition to cancer but without manifested cancer. Healthy volunteers and healthy patients are given the same procedure that the patient group receives. Investigators learn about the disease process by comparing the healthy volunteers' and healthy patients' images to the cancer patients' images.

Who can participate?

Magnetic Resonance Imaging (MRI) is an important tool used by doctors to detect, diagnose, and keep an eye on various diseases inside the body. We often use a special type of MRI that uses a substance known as a "contrast agent" to make the pictures even clearer and more helpful. You can either receive this substance through an injection into your body or take it as a drink before the scan.

In this research project, we are working on creating new ways to take pictures of cancer and keep track of how it is doing during treatment. To do this, we need the help of some people who are in good health to make sure we understand what a normal picture looks like. We also want to know what the pictures look like in people who are healthy but might have a higher chance of getting cancer because of their genes. These healthy volunteers and patients get the same imaging procedure that people with cancer get. By comparing the pictures from the healthy volunteers and patients to those from people with cancer, we can learn more about how the disease works.

What does the study involve?

We would like you to come for up to three study visits where you will have an MRI scan. We are studying three different ways of taking pictures: one involves getting an injection of a safe substance and then having a scan; another involves drinking a sweet drink and then having a scan; and the last one just requires an MRI scan. You might be asked to take part in one, two, or all three of these scans, depending on your agreement and if you are eligible. If you agree to have more than one scan, we will try to do them on the same visit. You can choose to take part in one scan and not in the others. If you are willing to have more than one scan, it will help us compare the different ways of taking pictures to see what each one is good for.

If possible, we would also like to check how reliable each method is by asking some people to come for an extra imaging session at some point during the study. This is optional and will help us understand the methods better.

During your visit(s), we might ask you to give a small sample of your blood. We will use this to check the levels of some simple substances in your blood. It will help us understand the pictures better. You do not have to do this if you do not want to.

What are the possible benefits and risks of participating?

Taking part in this study may not directly help you, but it could help doctors find better ways to check for and keep track of illnesses without using invasive methods. You will not be paid for taking part, we can cover your travel and parking costs.

Potential risks

MRI Scans: MRI scans are safe and do not involve X-rays or radioactivity. Some people might feel a bit closed-in (claustrophobic) or bothered by the noise, but you will be given earplugs and a squeeze-ball to help you feel more comfortable. The imaging software and hardware used are for research and not yet approved for routine diagnosis.

Incidental Findings: Although the scans are not part of your medical record, if we notice anything unusual, we will consult a specialist who may need to discuss it with you and your doctor.

Cannulation (inserting a small tube into a vein): This is a common procedure and is generally safe, but it might cause some discomfort or bruising at the insertion site. The cannula will be removed immediately after the scan.

Injection containing a substance called pyruvate or glucose: The injection is generally safe, with only mild and short-lasting side effects like flushing, feeling hot, dizziness or a metallic taste.

Allergic reactions are highly unlikely, but we are prepared to manage any issues that may arise.

Sweet drink containing a substance called deuterated glucose: Glucose is a natural sugar that our body uses for energy, and deuterium is a safe form of hydrogen that is also found naturally in small amounts in our body. Scientists have previously studied water and glucose containing deuterium in people, and they did not find safety concerns. Any potential side effects will be managed by our team.

Where is the study run from?

The study takes place in Cambridge University Hospitals NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

August 2022 to March 2028

Who is funding the study?

Cancer Research UK

Who is the main contact?

cu.h.radiologyresearch@nhs.net

Contact information

Type(s)

Principal investigator

Contact name

Prof Ferdia Gallagher

ORCID ID

<https://orcid.org/0000-0003-4784-5230>

Contact details

Department of Radiology, Level 5, Box 218
Addenbrooke's Hospital, Hills Road
Cambridge
United Kingdom
CB2 0QQ
+44 (0)1223 767062
ferdia.gallagher@nhs.net

Type(s)

Public, Scientific

Contact name

Dr Marta Wylot

Contact details

Department of Radiology, Level 5, Box 218
Addenbrooke's Hospital, Hills Road
Cambridge
United Kingdom
CB2 0QQ
+44 (0)1223 767062
marta.wylot@nhs.net

Type(s)

Scientific

Contact name

Ms Maria Zamora

Contact details

Box 218, Department of Radiology, Level 5
University of Cambridge School of Clinical Medicine
Cambridge Biomedical Campus
Cambridge
United Kingdom
CB2 0QQ

-

maria.zamoramora@nhs.net

Additional identifiers

Integrated Research Application System (IRAS)

319308

Protocol serial number

HeVoMRI v2.1 17 June 2023

Study information

Scientific Title

Development of novel multinuclear magnetic resonance techniques in healthy volunteers and healthy patients

Acronym

HeVoMRI

Study objectives

Significant differences exist in the imaging characteristics observed using Hyperpolarised MRI, sodium MRI and DMI between healthy volunteers and healthy patients.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 29/06/2023, Yorkshire & The Humber - Leeds East Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8018; leedseast.rec@hra.nhs.uk), ref: 23/YH/0127

Primary study design

Observational

Study design

Non-randomized physiological imaging study

Study type(s)

Other

Health condition(s) or problem(s) studied

Healthy volunteers and healthy patients with known specific genotypes

Interventions

Current interventions as of 13/08/2025:

This is a single-centre, non-randomised, prospective, physiological imaging study including the following imaging techniques:

- hyperpolarised ¹³C-MRSI
- DMI
- dynamic ²H-MRS and MRSI

Imaging the following parts of the body:

- brain
- chest
- abdomen/pelvis
- breast
- extremities

Each participant may have up to five optional repeat scans within six months of their first scan.

Imaging agent(s):

¹³C-pyruvate: a single IV injection of up to 40 mL at 0.4 mL/kg of [¹⁻¹³C]-pyruvate. The maximum injection rate will be 5 mL/s.

²H-glucose: oral dose of [6,6'-²H₂] glucose dissolved in 200 to 300 mL of potable water giving a dose of 0.75 g/kg body weight, with a maximum of 60 g.

Or

A single IV injection of [6,6'-²H₂]-glucose 10-25% (w/v) giving a dose of up to 0.5 g/kg body weight, with maximum 35 g. The maximum injection rate will be 5 mL/s.

Up to 6 administrations per study duration

Previous interventions:

This is a non-randomised, physiological imaging study split into three imaging techniques across the body including: brain, chest, abdomen/pelvis, breast or extremities.

MR imaging:

1. Following injection of ¹³C-pyruvate, using dynamic ¹³C MRI and MRSI in up to 40 healthy volunteers/healthy patients
2. Using Sodium MRI and MRSI in up to 40 healthy volunteers/healthy patients
3. Following oral consumption of a deuterated glucose drink or deuterated water, using dynamic deuterium metabolic MRI and MRSI imaging (DMI) in up to 40 healthy volunteers/healthy patients

Healthy volunteers/healthy patients will be allocated to one of these imaging techniques by the Chief Investigator or delegate. This will be based on the availability of kits for the Hyperpolarised MRI study, the availability of the deuterated drink for the DMI study and/or the availability of the research MRI scanner. If healthy volunteers/healthy patients are willing, they may be recruited to all three arms to enable direct comparison.

Each participant will be offered an optional repeat scan within 14 days of their first scan. This will either be a duplication of their first scan in order to determine whether these imaging techniques are repeatable or will be one of the other imaging techniques to determine whether these imaging techniques can provide complementary data when used in combination. Refusal to take part in this optional imaging will not impact their participation in the rest of the study.

Participants will not receive more than two injections of ¹³C-pyruvate and will not receive more than two deuterated glucose or two deuterated water drinks.

This single-centre study is being conducted at Addenbrooke's Hospital, Cambridge Biomedical Campus, UK.

Intervention Type

Other

Primary outcome(s)

Current primary outcome measure as of 13/08/2025:

1. ¹³C. Spatial maps of area under the curve (AUC) timecourse sums of signals from hyperpolarized pyruvate, lactate, and any other metabolites detected, and ratios between these metabolite AUCs. Also estimates of the kinetic rate constants of conversion between injected tracer pyruvate and the metabolites formed (lactate, other). The timecourse typically covers approximately 1 minute beginning approximately 16 seconds after the start of injection.
2. DMI (oral and IV). Spectral peak intensity ratios between ²H-water, ²H-glucose, ²H-glutamate (brain only), ²H-lactate and lipids. These will be either in spatial maps derived from 3D spectroscopic imaging, or in unlocalized spectra from the whole sensitive volume of the coil.
3. ²³Na. Maps of estimated millimolar sodium content over the 3D volume of tissue investigated. Optionally also maps of the ratio of intracellular-weighted signal to total ²³Na signal.
4. Demonstrate feasibility of DMI following ²H-glucose IV administration.

Previous primary outcome measure:

Using MRI imaging:

1. ¹³C. Spatial maps of area under the curve (AUC) timecourse sums of signals from hyperpolarized pyruvate, lactate, and any other metabolites detected, and ratios between these metabolite AUCs. Also estimates of the kinetic rate constants of conversion between injected tracer pyruvate and the metabolites formed (lactate, other). The timecourse typically covers approximately 1 minute beginning approximately 16 seconds after the start of injection.
2. DMI. Spectral peak intensity ratios between deuterated water, glucose, glutamate (brain only), lactate and lipids. These will be either in spatial maps derived from 3D spectroscopic imaging, or in unlocalized spectra from the whole sensitive volume of the coil.
3. Sodium. Maps of estimated millimolar sodium content over the 3D volume of tissue investigated. Optionally also maps of the ratio of intracellular-weighted signal to total sodium signal.

Key secondary outcome(s)

There are no secondary outcome measures

Completion date

31/03/2028

Eligibility

Key inclusion criteria

Inclusion criteria for healthy volunteers:

1. Over 18 years old
2. Able to and provide written informed consent to participate

3. If female, postmenopausal or if women of childbearing potential (WOCBP) using a suitable form of contraception
4. Capable of undergoing a minimum of one study visit

Inclusion criteria for healthy patients at risk for hereditary metabolic disease:

1. Over 18 years old
2. Able to and provide written informed consent to participate
3. If female, postmenopausal or if of childbearing potential (WOCBP) using a suitable form of contraception
4. Capable of undergoing a minimum of one study visit
5. Carrying a pathogenic variant in the genes for succinate dehydrogenase and undergoing asymptomatic surveillance but without tumour manifestation

Participant type(s)

Healthy volunteer, Patient

Healthy volunteers allowed

Yes

Age group

Mixed

Lower age limit

18 Years

Upper age limit

100 Years

Sex

All

Total final enrolment

0

Key exclusion criteria

The presence of any of the following will preclude participation as determined by the delegated investigator:

1. Contraindication or inability to tolerate MRI
2. Pregnant or actively breastfeeding woman
3. If using an intrauterine contraceptive device (IUCD) as a method of contraception the device should be MRI-safe at 3 T (researcher to confirm)
4. Clinically significant cardiac, pulmonary or neurological diseases as determined by the investigators
5. Laboratory abnormalities that may impact the study results although no screening will be required for entry into the study.
6. Any other significant medical or psychiatric history rendering the subject ineligible as deemed by the investigators

Date of first enrolment

29/08/2023

Date of final enrolment

30/04/2027

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Cambridge University Hospitals NHS Foundation Trust

Cambridge Biomedical Campus

Hills Road

Cambridge

England

CB2 0QQ

Sponsor information

Organisation

Cambridge University Hospitals NHS Foundation Trust

ROR

<https://ror.org/04v54gj93>

Funder(s)

Funder type

Research organisation

Funder Name

Cancer Research UK Cambridge Institute, University of Cambridge

Alternative Name(s)

Cancer Research UK Cambridge Institute, CRUK Cambridge Institute, CRUK CI, CRUK-CI

Funding Body Type

Government organisation

Funding Body Subtype

Research institutes and centers

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis. Access to trial IPD can be requested by qualified researchers engaging in independent scientific research and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact cu.h.radiologyresearch@nhs.net.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	HP version 4.0	23/10/2024	13/08/2025	No	Yes
Participant information sheet	HV version 4.0	23/10/2024	13/08/2025	No	Yes